Find Renal Cell Carcinoma (RCC) Clinical Trials Near You
A Phase 1/1b Open-label, Multi-center Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Status: Recruiting
Location: See all (11) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
This is a first-in-human study of BMS-986506 in participants with advanced Clear Cell Renal Cell Carcinoma (ccRCC). The primary objective of this study is to find out if BMS-986506 is safe and can be tolerated when taken alone or in combination by participants with ccRCC.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Participants must have histologically confirmed diagnosis of locally advanced or metastatic ccRCC.
• For part 1: Participants must have already had at least two different treatment plans in the past, including immunotherapy and a targeted therapy.
• For part 2: Participants must have had at least one standard treatment plan that included both a PD-1/L1 inhibitor and a VEGF-TKI (either together or one after the other).
• Part 3: Participants must have had at least 1 standard treatment regimen (including a PD-1/L1 checkpoint inhibitor and/or a VEGF-TKI).
• Part 4: Participants must not have received prior systemic therapy for metastatic RCC, but may have received prior adjuvant therapy for completely resected RCC with PD-1 inhibitor if recurrence occurred at least 6 months after the last dose of adjuvant or neoadjuvant therapy.
• Eastern Cooperative Oncology Group performance status of 0 to 1.
Locations
United States
Massachusetts
Dana-Farber Cancer Institute
RECRUITING
Boston
New York
Memorial Sloan Kettering Cancer Center
RECRUITING
New York
Pennsylvania
Fox Chase Cancer Center
RECRUITING
Philadelphia
Tennessee
SCRI Oncology Partners
RECRUITING
Nashville
Texas
START San Antonio
RECRUITING
San Antonio
Other Locations
Canada
Arthur J.E. Child Comprehensive Cancer Centre
RECRUITING
Calgary
France
Gustave Roussy
RECRUITING
Villejuif
Italy
Local Institution - 0031
NOT_YET_RECRUITING
Roma
Local Institution - 0033
NOT_YET_RECRUITING
Verona
Spain
Hospital Universitari Vall d'Hebron
RECRUITING
Barcelona
Hospital Universitario Reina Sofia
RECRUITING
Córdoba
Contact Information
Primary
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Clinical.Trials@bms.com
855-907-3286
Backup
First line of the email MUST contain NCT # and Site #.
Time Frame
Start Date:2026-01-15
Estimated Completion Date:2031-04-03
Participants
Target number of participants:281
Treatments
Experimental: Part 1A BMS-986506 Monotherapy Escalation
Experimental: Part 2A BMS-986506 Monotherapy Expansion
Experimental: Part 2B BMS-986506 Monotherapy Expansion
Experimental: Part 3A BMS-986506 + Pumitamig Combination Dose Escalation